Radioimmunotherapy dose estimation in patients with B-cell lymphoma.
Trials of radiolabeled antibody therapy in patients with B-cell lymphoma have been the most promising of any in radioimmunotherapy. Response rates of greater than 90% with many complete remissions have been reported by several groups using either low (185-370 MBq) or high (8.6-22.5 GBq) doses of I-131-labeled antibodies against B-cell antigens. Estimated doses delivered to normal organs have ranged from 0.2 to 2.2 mGy/MBq and have shown similar interpatient variation in all series, despite differences in antibody specificity and dosimetric techniques. Tumor doses have ranged from 0.5 to 5.4 mGy/MBq. There has been little correlation of tumor response with estimated tumor dose. Toxicity has been limited to bone marrow suppression which has been greater with the higher amounts of I-131. An advantage for a particular antibody specificity or for high dose compared to multiple low doses has yet to be demonstrated.
Cooper Hospital/University Medical Center, Camden, New Jersey 08103.
J A
JA
Siegel
D M
DM
Goldenberg
C C
CC
Badger
D006801:Humans; D016393:Lymphoma, B-Cell / Q000532:radiotherapy*; D016499:Radioimmunotherapy / Q000379:methods*; D011874:Radiometry / Q000379:methods*; D011879:Radiotherapy Dosage